Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial

Prymula, Roman; Bergsaker, Marianne Riise; Esposito, Susanna; Gothefors, Leif; Man, Sorin Claudiu; Снегова, Н Ф; Štefkovičová, Mária; Usonis, Vytautas; Wysocki, Jacek; Douha, Martine; Vassilev, Ventzislav; Nicholson, Ouzama; Innis, Bruce L.; Willems, Paul

doi:10.1016/s0140-6736(12)61461-5

Cited by 85 publications

(100 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…33,[37][38][39] However, the distinguishing feature of this analysis is the application of 2-dose vaccine efficacy estimates from a recent clinical trial. 25 The model used the conservative assumption that exogenous immunity boosting existed, and as expected, this resulted in a temporary increase in the number of zoster cases. The risks and benefits of vaccination need to be assessed in terms of the impact on zoster epidemiology.…”

Section: Discussionmentioning

confidence: 99%

“…After 2 doses of MMRV, most partially protected vaccine recipients become fully protected. Breakthrough cases (varicella or zoster cases after vaccination) are assumed to be milder than naturally acquired cases of varicella or zoster 25 and that vaccination also results in lower infection and reactivation rates. All input parameters and vaccine assumptions including the differential equations used in the model are provided in Appendix A.…”

Section: Model Descriptionmentioning

confidence: 99%

See 1 more Smart Citation

The Impact of 2-Dose Routine Measles, Mumps, Rubella, and Varicella Vaccination in France on the Epidemiology of Varicella and Zoster Using a Dynamic Model With an Empirical Contact Matrix

Ouwens¹,

Littlewood²,

Sauboin

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Model Descriptionmentioning

confidence: 99%

The Impact of 2-Dose Routine Measles, Mumps, Rubella, and Varicella Vaccination in France on the Epidemiology of Varicella and Zoster Using a Dynamic Model With an Empirical Contact Matrix

Ouwens¹,

Littlewood²,

Sauboin

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

show abstract

“…3,6 A submission to fund two-dose varicella vaccination under the Australian National Immunization Programme was rejected in 2008 due to uncertainty regarding the incremental cost-effectiveness of the second dose. 42 However, emerging data on further declines during the two-dose programme in the USA 43,44 and recent evidence indicating that breakthrough varicella was almost seven times less likely to occur in two-compared with one-dose vaccine recipients 45 provide empirical evidence of the potential benefits of a two-dose schedule.…”

Section: Varicella Vaccination and Admissions To Hospitals In Australiamentioning

confidence: 99%

Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study

Heywood

Wang

Macartney

et al. 2014

Bull. World Health Organ.

View full text Add to dashboard Cite

“…[13][14][15] MMRV vaccines were licensed on the basis of noninferior immunogenicity of the antigenic components compared with simultaneous administration of MMR and varicella vaccines 16,17 ; an efficacy study for 2 doses of MMRV vaccine was performed after licensure. 18 Efficacy studies conducted used vaccines with varying concentrations of the Oka strain, making comparisons across studies and inference of results to licensed vaccine formulations difficult; moreover, vaccine performance may be different under conditions of real-world use (vaccine effectiveness [VE]). Therefore, postlicensure evaluations of VE are important to inform public health programs and policies.…”

mentioning

confidence: 99%

Global Varicella Vaccine Effectiveness: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

CONTEXT: Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1-or 2-dose schedules. OBJECTIVE:We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children.DATA SOURCES: Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014. STUDY SELECTION:Publications that reported original data on dose-specific varicella VE among immunocompetent children. DATA EXTRACTION:We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design. RESULTS:The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design.LIMITATIONS: VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella. CONCLUSIONS:One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella.a National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and b Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland Dr Marin conceptualized and designed the study, reviewed the articles and collected the data, supervised the analysis, interpreted the data, drafted the initial manuscript, and revised the manuscript; Dr Marti conceptualized the study, reviewed part of the articles, interpreted the data, and reviewed and revised the manuscript; Ms Kambhampati carried out the meta-analyses, interpreted the data, and reviewed the manuscript; Dr Jeram conducted an initial literature review, reviewed part of the articles and collected the data, and reviewed the manuscript; Dr Seward conceptualized and designed the study, reviewed part of the articles, critically reviewed the manuscript, and interpreted the data; and all authors approved the fi nal manuscript as submitted.The fi ndings and conclusions in this report are those of the authors and do not necessarily represent the offi cial position of the Centers for Disease Control and Prevention. For authors affi liated with the World Health Organization, the authors alone are responsible for the views expressed in this publication ...

show abstract

Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial

Cited by 85 publications

References 33 publications

The Impact of 2-Dose Routine Measles, Mumps, Rubella, and Varicella Vaccination in France on the Epidemiology of Varicella and Zoster Using a Dynamic Model With an Empirical Contact Matrix

The Impact of 2-Dose Routine Measles, Mumps, Rubella, and Varicella Vaccination in France on the Epidemiology of Varicella and Zoster Using a Dynamic Model With an Empirical Contact Matrix

Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study

Global Varicella Vaccine Effectiveness: A Meta-analysis

Contact Info

Product

Resources

About